Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Obesity medicine experts clear up common misunderstandings and misinformation about these powerful weight loss medications ...

GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...

Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss ...

Lexaria Bioscience (LEXX) provides a glucagon-like peptide-1 strategic update following important industry developments reported both by Pfizer ...

Both GLP-1 RAs and SGLT2is are associated with a reduced risk for Alzheimer disease and related dementias among people with T2D.

Researchers link GLP1 agonists to depression risk in some users and call for personalized prescribing based on genetic ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...

MetaVia (MTVA) reported additional top-line results from the multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, ...